PURPOSE: To evaluate whether metabolic changes in the primary tumour during and after preoperative radiochemotherapy (RCT) can predict the histopathological response in patients with locally advanced rectal cancer as well as disease-free survival (DFS) and overall survival (OS). METHODS: Consecutive patients with cT2-4 N0-2 rectal adenocarcinoma were included. (18)F-FDG PET/CT was performed at baseline, at the end of the second week of RCT (early PET/CT) and before surgery (late PET/CT). The PET/CT results were compared with histopathological data (ypT0 N0 vs. ypT1-4 N0-2 as well as TRG1 vs.TRG2-5) and survival. RESULTS: The study included 126 patients. Among 124 patients in whom TNM classification was available, 28 (22.6 %) were ypT0 N0, and among all 126 patients, 31 (24.6 %) were TRG1. The areas under the curve of the early response index (RI) for identifying non-complete pathological response (non-cPR) were 0.74 (95 % CI 0.61 - 0.87) for ypT1-4 N0-2 patients and 0.75 (95 % CI 0.62 - 0.88) for TRG2-5 patients. The optimal cut-off for differentiating patients with non-cPR and cPR was found to be a reduction of 61.2 % (83.1 % sensitivity and 65 % specificity in ypT1-4 N0-2 patients; 85.4 % sensitivity and 65.2 % specificity in TRG2-5 patients). The optimal cut-off for late RI could not be found. The qualitative analysis of images obtained after RCT demonstrated 81.5 % sensitivity and 61.3 % specificity in predicting TRG2-5. After a median follow-up of 68 months, the low number of patients with local/distant recurrence or who had died did not allow the value of PET/CT for predicting DFS and OS to be calculated. CONCLUSION: The early assessment of response to RCT by (18)F-FDG PET/CT can predict non-cPR allowing practical modification of preoperative treatment. Conversely, late RI is not sufficiently accurate for guiding the decision as to whether local excision or even observation is appropriate in an individual patient. Qualitative analysis of late PET/CT images is also not sensitive enough alone to rule out the presence of residual disease.
PURPOSE: To evaluate whether metabolic changes in the primary tumour during and after preoperative radiochemotherapy (RCT) can predict the histopathological response in patients with locally advanced rectal cancer as well as disease-free survival (DFS) and overall survival (OS). METHODS: Consecutive patients with cT2-4 N0-2 rectal adenocarcinoma were included. (18)F-FDG PET/CT was performed at baseline, at the end of the second week of RCT (early PET/CT) and before surgery (late PET/CT). The PET/CT results were compared with histopathological data (ypT0 N0 vs. ypT1-4 N0-2 as well as TRG1 vs.TRG2-5) and survival. RESULTS: The study included 126 patients. Among 124 patients in whom TNM classification was available, 28 (22.6 %) were ypT0 N0, and among all 126 patients, 31 (24.6 %) were TRG1. The areas under the curve of the early response index (RI) for identifying non-complete pathological response (non-cPR) were 0.74 (95 % CI 0.61 - 0.87) for ypT1-4 N0-2 patients and 0.75 (95 % CI 0.62 - 0.88) for TRG2-5 patients. The optimal cut-off for differentiating patients with non-cPR and cPR was found to be a reduction of 61.2 % (83.1 % sensitivity and 65 % specificity in ypT1-4 N0-2 patients; 85.4 % sensitivity and 65.2 % specificity in TRG2-5 patients). The optimal cut-off for late RI could not be found. The qualitative analysis of images obtained after RCT demonstrated 81.5 % sensitivity and 61.3 % specificity in predicting TRG2-5. After a median follow-up of 68 months, the low number of patients with local/distant recurrence or who had died did not allow the value of PET/CT for predicting DFS and OS to be calculated. CONCLUSION: The early assessment of response to RCT by (18)F-FDG PET/CT can predict non-cPR allowing practical modification of preoperative treatment. Conversely, late RI is not sufficiently accurate for guiding the decision as to whether local excision or even observation is appropriate in an individual patient. Qualitative analysis of late PET/CT images is also not sensitive enough alone to rule out the presence of residual disease.
Authors: Ruud G P M van Stiphout; Guido Lammering; Jeroen Buijsen; Marco H M Janssen; Maria Antonietta Gambacorta; Pieter Slagmolen; Maarten Lambrecht; Domenico Rubello; Marcello Gava; Alessandro Giordano; Eric O Postma; Karin Haustermans; Carlo Capirci; Vincenzo Valentini; Philippe Lambin Journal: Radiother Oncol Date: 2010-12-20 Impact factor: 6.280
Authors: N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber Journal: Int J Radiat Oncol Biol Phys Date: 1999-07-15 Impact factor: 7.038
Authors: Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong Journal: Ann Surg Date: 2005-05 Impact factor: 12.969
Authors: Tobias Leibold; Timothy J Akhurst; David B Chessin; Henry W Yeung; Homer Macapinlac; Jinru Shia; Bruce D Minsky; Leonard B Saltz; Elyn Riedel; Madhu Mazumdar; Philip B Paty; Martin R Weiser; W Douglas Wong; Steven M Larson; José G Guillem Journal: Ann Surg Oncol Date: 2011-04-08 Impact factor: 5.344
Authors: Marco H M Janssen; Hugo J W L Aerts; Jeroen Buijsen; Philippe Lambin; Guido Lammering; Michel C Öllers Journal: Int J Radiat Oncol Biol Phys Date: 2011-03-09 Impact factor: 7.038
Authors: G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche Journal: Surg Endosc Date: 2007-10-18 Impact factor: 4.584
Authors: F Alongi; S Fersino; R Mazzola; A Fiorentino; N Giaj-Levra; F Ricchetti; R Ruggieri; G Di Paola; M Cirillo; S Gori; M Salgarello; G Zamboni; G Ruffo Journal: Clin Transl Oncol Date: 2016-06-07 Impact factor: 3.405
Authors: Pierre Lovinfosse; Marc Polus; Daniel Van Daele; Philippe Martinive; Frédéric Daenen; Mathieu Hatt; Dimitris Visvikis; Benjamin Koopmansch; Frédéric Lambert; Carla Coimbra; Laurence Seidel; Adelin Albert; Philippe Delvenne; Roland Hustinx Journal: Eur J Nucl Med Mol Imaging Date: 2017-10-18 Impact factor: 9.236
Authors: Antonio Avallone; Luigi Aloj; Biagio Pecori; Corradina Caracò; Alfonso De Stefano; Fabiana Tatangelo; Lucrezia Silvestro; Vincenza Granata; Francesco Bianco; Carmela Romano; Francesca Di Gennaro; Alfredo Budillon; Antonella Petrillo; Paolo Muto; Gerardo Botti; Paolo Delrio; Secondo Lastoria Journal: J Nucl Med Date: 2019-03-15 Impact factor: 10.057
Authors: Antonella Petrillo; Roberta Fusco; Mario Petrillo; Vincenza Granata; Paolo Delrio; Francesco Bianco; Biagio Pecori; Gerardo Botti; Fabiana Tatangelo; Corradina Caracò; Luigi Aloj; Antonio Avallone; Secondo Lastoria Journal: Oncotarget Date: 2017-01-31